April 23, 2019 / 1:18 PM / 3 months ago

Teva to stop developing cluster headache treatment

April 23 (Reuters) - Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches.

The company said the decision was taken after an analysis of late-stage data showed that the drug was unlikely to meet the main goal of the study.

Reporting by Manas Mishra in Bengaluru; Editing by James Emmanuel

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below